The increased therapeutic window of intra-arterial injection compared with intravenous injection could be an interesting incentive to explore the possibility of PSMA-targeted peptide radioligand therapy for a subset of ICC patients. Here, FOLH1 is linked to intrahepatic cholangiocarcinoma.